AbbVie's DEI Employment Practices: What the Company's Own Documents Show — and What They Mean for Employees

Published August 27, 2026 · Last updated August 27, 2026 · By Fett Law — Michigan Employment Discrimination Attorneys

AbbVie Inc.'s own SEC filings and published reports document a demographic employment regime running from 2019 through 2024: an ESG goal weighted 10% of every named executive officer's short-term incentive, inside which "all senior leaders" carried "a goal aligned to executing the EEDI strategy"; a proxy statement telling shareholders that "equity, equality, diversity, and inclusion (EEDI) goals are incorporated into our executive compensation programs for all executives"; a dedicated diversity-recruiting team built on partnerships with nine historically Black colleges and Hispanic-serving institutions; numeric race and sex targets for the lawyers staffed to AbbVie matters; and mentoring, sponsorship and internship programs described as being for "diverse" talent. Between the March 2024 proxy and the March 2025 proxy, AbbVie deleted the diversity clause from that compensation sentence and left the rest of the sentence intact. AbbVie is a Department of Veterans Affairs contractor. Similar practices were the basis of IBM's $17 million False Claims Act settlement with the U.S. Department of Justice in April 2026 and a $21.5 million Deloitte settlement effective August 21, 2026.

Key facts

Did AbbVie tie executive pay to diversity goals?

The mechanism is described in AbbVie's own ESG Action Reports with unusual precision. The 2021 report:

"In 2021, our executive officers maintained a formal goal to protect AbbVie's reputation across a range of ESG topics aligned to our long-term company strategy and ESG framework. The ESG goal was weighted 10% within the short-term incentive program for each executive officer. As part of this ESG goal category, all senior leaders, including executive officers, commit to executing our Equity, Equality, Diversity and Inclusion (EEDI) strategy."

AbbVie Inc., 2021 ESG Action Report, p. 10

The 2022 report repeats the structure and reports that it continued:

"In 2022, our Named Executive Officers (NEOs) continued to have a formal goal aligned to driving AbbVie's ESG framework. The ESG goal was weighted 10% within the short-term incentive program for each NEO. As part of this ESG goal category, all senior leaders, including the NEOs, continued to have a goal aligned to executing the EEDI strategy."

AbbVie Inc., 2022 ESG Action Report, p. 11

And the 2023 report carries the identical construction a third year:

"In 2023, our Named Executive Officers (NEOs) continued to have a formal goal aligned to driving AbbVie's ESG framework. The ESG goal was weighted 10% within the short-term incentive program for each NEO. As part of this ESG goal category, all senior leaders, including the NEOs, continued to have a goal aligned to executing the EEDI strategy."

AbbVie Inc., 2023 ESG Action Report, p. 8

AbbVie also told shareholders who was accountable for the strategy those goals were measured against:

"The strategy and its implementation are driven and overseen by our CEO, Chief Equity Officer and the Executive Leadership team who set formal goals and are held accountable for our performance in this area."

AbbVie Inc., 2021 ESG Action Report, p. 34; repeated in the 2022 ESG Action Report, p. 11

What AbbVie told shareholders in the proxy

The compensation linkage was not confined to a sustainability report. It appears in AbbVie's proxy statements — documents filed with the Securities and Exchange Commission and voted on by shareholders. It first appears in the proxy filed March 21, 2022, in the governance highlights:

"All executives have ESG and equity, equality, diversity, and inclusion goals"

AbbVie Inc., 2022 Proxy Statement (DEF 14A, filed March 21, 2022), governance highlights

The proxies filed March 20, 2023 and March 18, 2024 restate it in a fuller sentence, identical in both years:

"ESG and equity, equality, diversity, and inclusion (EEDI) goals are incorporated into our executive compensation programs for all executives"

AbbVie Inc., 2023 Proxy Statement (DEF 14A, filed March 20, 2023) and 2024 Proxy Statement (DEF 14A, filed March 18, 2024)

What this meant in practice. AbbVie represented to its shareholders that every executive's annual incentive included a goal category worth 10% of the short-term incentive, and that executing a strategy whose stated cornerstones included "attract and source talent" sat inside that category. A compensation component that responds to progress on a demographic strategy is the first of the four practice categories the Justice Department identified in the IBM settlement — what the Department described as a "diversity modifier" on bonus compensation.

The honest limits belong here too. AbbVie never published how heavily the EEDI component weighed inside the 10% ESG goal, what it was measured against numerically, whether the goal was ever scored down, or whether any executive's payout actually moved because of it. The company's public documents establish that the mechanism existed and that senior leaders carried goals under it. What those goals actually said, how they were scored, and what managers below the executive level were told to do about them are internal facts — the kind that live with the people who wrote and administered the plans.

Sources: 2021 ESG Action Report · 2022 ESG Action Report · 2023 ESG Action Report · 2022 Proxy Statement · 2024 Proxy Statement.

Did AbbVie use race- and sex-conscious recruiting?

The 2020 ESG Action Report announces the build-out:

"In 2020, we expanded our diversity recruiting strategy to include a dedicated team and are expanding our focused partnerships with Historically Black Colleges and Universities (HBCUs) as well as Hispanic Serving Institutions."

AbbVie Inc., 2020 ESG Action Report, p. 31

The 2021 report puts a number on it and states the purpose:

"Leveraging strategic partnerships with organizations and educational institutions, AbbVie continues to build a robust pool of diverse talent today and for years to come. With an emphasis on our early career pipeline, a dedicated team of AbbVie relationship managers and recruiters have developed direct school partnerships with nine Historically Black Colleges and Universities (HBCUs) and Hispanic-Serving Institutions (HSIs)."

AbbVie Inc., 2021 ESG Action Report, p. 36

Sourcing was not incidental to the program — AbbVie identified it as structural. The company described its five-year strategy in the same report:

"Our five-year EEDI strategy, launched in 2019, focuses on several cornerstones of success: drive awareness & understanding; attract and source talent; develop and engage talent; and create connections and community."

AbbVie Inc., 2021 ESG Action Report, p. 34; the same four cornerstones appear in the 2022 ESG Action Report, p. 40

And AbbVie told shareholders the strategy was operationalized down to the business-unit level:

"Each of these strategic areas has specific objectives and associated initiatives and include implementation plans organized by business function and geography."

AbbVie Inc., 2021 ESG Action Report, p. 34

Two things should be said about this category, in both directions.

First, outreach that widens a candidate pool without changing who is selected from it generally sits on the lawful side of the line. Recruiting at nine HBCUs and Hispanic-Serving Institutions adds candidates; it does not, by itself, remove anyone from consideration. Nothing in AbbVie's published documents describes a rule requiring a slate to contain a candidate of a particular race or sex before a requisition could advance — which is precisely the practice that sat at the center of the IBM and Deloitte matters. This page does not claim AbbVie had one.

Second, sourcing described as a cornerstone of a strategy that every senior leader carried compensation goals against is not the same thing as a career fair. "Attract and source talent" with "implementation plans organized by business function" means somebody in each function had an objective, and somebody measured it. Whether a protected trait actually changed who was interviewed or hired in a given requisition is a question the public documents cannot answer in either direction. The recruiters, talent-acquisition leaders and hiring managers who ran those plans are the people who know.

Note also what happened to this language. The HBCU and HSI recruiting description does not appear in AbbVie's 2023, 2024 or 2025 ESG Action Reports. By the 2022 report the HBCU relationship is reframed away from hiring entirely — toward clinical trials and health equity, "to improve health equity, advance clinical research education, focus on patient-centricity and drive access to clinical trial programs."

Sources: 2020 ESG Action Report · 2021 ESG Action Report · 2022 ESG Action Report.

Did AbbVie set numeric race and sex targets for the lawyers on its matters?

The page is titled "Committed to improving diversity in law." It survives at a legacy address on abbvie.com and carries no publication or last-updated date. It states:

"We have set a goal to develop a diverse slate of outside counsel talent by 2023, and we are seeing good progress."

AbbVie Inc., "Committed to improving diversity in law," abbvie.com. No publication date is displayed on the page; verified live August 2026.

"We have established concrete targets for women and minority partners at our top firms: the percentage of hours each group bills annually on AbbVie's matters."

AbbVie Inc., "Committed to improving diversity in law," abbvie.com

Under a heading the company itself labels "Measurable goals for outside counsel," the page lists the targets:

"A mix of at least 50% underrepresented lawyers serving on AbbVie matters"

"Minority partner representation approximately doubles (moving from 8% in 2018 to 15% by 2023)"

"Equal female and male partners serving on legal matters"

AbbVie Inc., "Committed to improving diversity in law," abbvie.com, "Measurable goals for outside counsel"

The same page describes an internship program defined by the same criteria, and reports its placement rate:

"100% of our diverse interns from the IP Group Intern Program have received offers for summer positions or full-time employment upon graduation from top firms."

AbbVie Inc., "Committed to improving diversity in law," abbvie.com, describing its "Intellectual Property (IP) first year law school internship program for diverse students"

What this meant in practice — and who it reached. A target expressed as a percentage of billed hours by demographic group is an instruction about staffing. If at least half the lawyer hours on AbbVie's matters are to be billed by "underrepresented lawyers," and partner hours are to be split equally between women and men, then a law firm that wants to keep AbbVie's work has a reason to consider race and sex when deciding which of its associates and partners it assigns to that work. The lawyers affected are employees of those firms, not of AbbVie — but their assignments, their billable hours, and in a partnership-track profession their advancement, can turn on it.

What this is not. AbbVie did not publish any equivalent numeric target for its own employees. The company reported workforce demographics as achieved statistics year over year — 54% women globally in 2020 rising to 56% by 2024; 33% of the U.S. workforce from "underrepresented" populations in 2020 rising to 39% by 2024 — but this review located no forward-looking percentage, no "by 2025" workforce goal, and no "double" commitment for AbbVie's own headcount in any ESG Action Report, disclosure supplement or proxy from 2020 through 2026. That distinction matters and this page keeps it: reported results are not targets, and nothing here should be read as saying AbbVie set a quota for its own hiring.

Source: AbbVie, "Committed to improving diversity in law" — live at a legacy address as of August 2026 and no longer reachable from the company's current navigation. Download rather than bookmark.

Did AbbVie run programs targeted by race or sex?

The 2021 ESG Action Report describes the two executive-access programs:

"Our thriving Executive Diversity Mentoring Program (EDMP) pairs high performing, diverse talent with AbbVie senior executive leaders for a one-on-one mentoring partnership over ten months. We also launched our Executive Sponsorship Program in 2021… This program builds upon our culture of mentorship, with an emphasis on equity, creating more pathways for talent of diverse backgrounds and experiences to be successful at AbbVie."

AbbVie Inc., 2021 ESG Action Report, pp. 36–37

The 2020 report describes the same programs a year earlier, alongside a leadership program defined by sex:

"This year, we expanded our existing Executive Diversity Mentoring Program and launched a formal Sponsorship program—creating more opportunities for our talented pipeline to learn and grow while being supported by successful leaders."

"In 2020, we continued to develop and engage our diverse talent through initiatives such as our global Women's Leadership Journey, which provides a broader awareness of and exposure to the skills and perspectives needed to excel into senior roles."

AbbVie Inc., 2020 ESG Action Report, p. 31

Why access programs are the category that most often produces a claim. Mentoring by a senior executive, a formal sponsor who advocates for your promotion, and a leadership program that gives "exposure to the skills and perspectives needed to excel into senior roles" are not ceremonial. They are the mechanisms by which people get promoted. The Deloitte settlement describes exactly this: programs "where eligibility to participate was limited on the basis of race and sex," "designed to boost the career prospects of these individuals over others," with sponsors instructed to "publicly advocate for a promotion or leadership role." An employee excluded from that kind of program on the basis of race or sex has lost something with an identifiable career value — and after Muldrow v. City of St. Louis (2024), a plaintiff need show only "some harm" to a term or condition of employment, not a significant or material disadvantage.

AbbVie's published descriptions say who these programs were for — "diverse talent," "talent of diverse backgrounds," women — but they do not state eligibility rules, publish selection criteria, or say whether anyone was formally excluded. Whether a specific employee was screened out because of race or sex, or simply never nominated, is a fact question. The nomination lists, sponsor assignments and program rosters would answer it.

The Employee Resource Groups, as they read today

AbbVie's live Employee Resource Group page lists seven groups — AbbVie Pride, Ability at AbbVie, AHORA (Hispanic/Latino), Asian Leadership Network, Black Business Network, a veterans group, and Women Leaders in Action — and frames them this way:

"Our Employee Resource Groups (ERGs) are open to all employees."

AbbVie Inc., "Employee Resource Groups," abbvie.com, verified live August 2026

The stated missions of the individual groups are narrower than the membership rule. The Black Business Network's is "[w]e support the retention and advancement of Black talent within AbbVie." AHORA's is "[w]e're building a stronger Latinx/Hispanic workforce by attracting, developing and retaining Latinx/Hispanic talent." Women Leaders in Action "enables and empowers women globally to reach their full potential."

An open-membership disclaimer sitting on top of a race- or sex-defined objective is a common pattern in post-2023 corporate disclosures, and it does not resolve the legal question by itself. A group anyone may join is generally not a problem. A group whose purpose is the "retention and advancement" of one racial group, and which functions as a channel to sponsorship, visibility or promotion, can become one — depending on what it actually did and who actually benefited.

Sources: 2020 ESG Action Report · 2021 ESG Action Report · Employee Resource Groups.

What did AbbVie remove from its disclosures — and when?

Put the three sentences next to each other. All three are from SEC-filed proxy statements, and all three are still available on EDGAR.

The sentence frame survived. Only the diversity clause was cut, and it was cut between the March 2024 and March 2025 filings.

The 2025 proxy also did something a compliance lawyer will recognize. Where the 2023 and 2024 proxies described the board's role as "oversight of the company's equity, equality, diversity, and inclusion strategy," the 2025 proxy reads:

"(2) oversight of the company's lawfully-compliant equity, equality, diversity, and inclusion strategy"

AbbVie Inc., 2025 Proxy Statement (DEF 14A, filed March 24, 2025). Emphasis added. The qualifier "lawfully-compliant" appears in AbbVie's 2025 filings and in no other year.

That hedge lasted one year. The phrase "equity, equality, diversity, and inclusion" does not appear in AbbVie's 2026 proxy statement at all — nor did it appear in the 2020 proxy, before the program was built.

What else came out

• The EEO-1 reference. AbbVie's 2024 proxy touted having "disclosed detailed data on the diversity of AbbVie's U.S. workforce by publishing AbbVie's EEO-1 report on our website starting in 2020." The 2025 proxy contains no EEO-1 reference.
• The compensation linkage in the ESG reports. The 2021, 2022 and 2023 ESG Action Reports each state that the 10%-weighted ESG goal included a goal aligned to executing the EEDI strategy. The 2024 report does not. The 2025 report keeps the weighting and drops the tie-in entirely: "Compensation Committee: Oversees ESG goals taken by our named executive officers, with a goal weighting of 10%."
• The Chief Equity Officer. The title appears in AbbVie's ESG Action Reports from 2020 through 2024. It does not appear in the 2025 report. The officer on the company's current live page is titled "Vice President, EEDI."
• The workforce demographics. The 2024 ESG Disclosure Supplement dropped the U.S. race and ethnicity breakdown and the "underrepresented populations" metric. The 2025 ESG Action Report and its disclosure supplement contain no workforce demographics at all beyond women-in-management percentages — no race data, and no occurrence of "diversity," "equity," "inclusion," "EEDI" or "Chief Equity Officer" anywhere in the supplement.
• The pay-equity commitment. The 2021 report stated: "AbbVie is committed to pay equity. We conduct annual pay-equity analyses to ensure pay is equitable across genders and ethnicities among United States employees." By 2024 the reference to ethnicities was gone: "We are committed to pay equity and we regularly review pay to ensure our pay is fair and equitable." In the 2025 report and supplement, no pay-equity claim was located at all.
• One word inside a program description. The 2021 report describes the Executive Diversity Mentoring Program as pairing "high performing, diverse talent" with senior executives. AbbVie's current live page describes one-on-one mentoring that pairs "high performing talent" with AbbVie senior executives. Same program, one adjective deleted, and the program's name no longer appears.
• The main EED&I page. It is still live and still carries the title. What it no longer carries: the five-year strategy, the Chief Equity Officer, any representation statistics, any description of hiring or sourcing, any pay-equity data, and any EEO-1 link. What remains is principles language — "Inclusion at AbbVie is the determination we each make to make a difference – for all."

A note on preservation. Unlike several companies in this series, AbbVie has not deleted its reports — every ESG Action Report from 2020 through 2025 still loads and every one is linked below. But two of them sit at addresses with no year in the filename and are overwritten each publication cycle: the current ESG Action Report and the company's EEO-1 report, which as of this writing carries data "as of December 31, 2024." AbbVie posts only the single most recent EEO-1; prior years are not offered on the site. If any part of your situation depends on what these documents say, download the PDF. A file that lives at an address the next edition will overwrite is not archived by bookmarking it.

How AbbVie's DEI program changed, 2019–2026

Why these practices matter legally

Title VII protects everyone, in both directions

Title VII makes it unlawful for an employer to discriminate against any individual with respect to compensation, terms, conditions or privileges of employment because of race, color, religion, sex or national origin. It does not create a protected class of beneficiaries and an unprotected class of everyone else. In Ames v. Ohio Department of Youth Services, decided June 5, 2025, a unanimous Supreme Court rejected the "background circumstances" rule that several federal circuits had used to require majority-group plaintiffs to make an extra showing before their claims could proceed. In Muldrow v. City of St. Louis (2024), the Court held that a plaintiff challenging a discriminatory job transfer need show only "some harm" to an identifiable term or condition of employment — not a "significant" or "material" disadvantage. That standard reaches actions well short of firing: a lost assignment, a lateral move, an exclusion from a mentoring or sponsorship program that leads to promotion.

Section 1981 reaches race discrimination in employment contracts

42 U.S.C. § 1981 guarantees all persons the same right to make and enforce contracts as is enjoyed by white citizens, and it applies to employment relationships. Three features matter for anyone evaluating an older claim: it carries a four-year limitations period, it requires no charge with the Equal Employment Opportunity Commission before suit, and it has no damages cap.

The False Claims Act route for federal contractors

On April 10, 2026, the U.S. Department of Justice announced that IBM would pay $17,077,043 to resolve False Claims Act allegations that it failed to comply with anti-discrimination requirements in its federal contracts — the first settlement under the DOJ's Civil Rights Fraud Initiative. In August 2026 the government resolved a second, larger matter: under a settlement agreement effective August 21, 2026, five Deloitte entities agreed to pay $21,500,000, of which $9,995,000 was restitution, covering conduct from January 1, 2017 through the settlement date. The certification hook is specific — Title VII as incorporated into federal contracts and FAR clause 52.222-26 — and the government's theory reached not only what Deloitte certified to its contracting agencies but what it "publicly represented" about its compliance. The agreement adds a second and independent theory: that Deloitte "allocated costs to its federal government contracts relating to these practices and sought payment and reimbursement under its federal government contracts for such costs." The whistleblower was paid $4,300,000. Both settlements resolved allegations only, with no determination of liability, and Deloitte denies the conduct.

The government's description of the Deloitte conduct is worth reading next to AbbVie's own disclosures, because the architecture is recognizable. The United States contended that Deloitte maintained "non-public race and sex-based workforce composition goals for business units," that senior partners, principals and managing directors "were evaluated, in part, based on their contributions to helping Deloitte achieve its workforce composition goals" and "stood to lose tens of thousands of dollars per year," and that it ran programs "where eligibility to participate was limited on the basis of race and sex," "designed to boost the career prospects of these individuals over others." AbbVie's published documents establish a compensation goal category carrying execution of a demographic strategy, and programs described as being for "diverse" talent. They do not establish non-public numeric composition goals, a dollar figure at risk, or an express eligibility restriction — and this page does not assert any of those.

AbbVie's position on the government-business side is documented. The Federal Procurement Data System lists ABBVIE US LLC as a registered federal vendor with more than 600 contract action records and Department of Veterans Affairs contracting activity running from at least February 2018 through April 2025. AbbVie's FY2025 Form 10-K separately describes statutory pricing obligations to the VA, the Department of Defense and Public Health Service entities under the Veterans Health Care Act of 1992, participation in the 340B program and the Medicaid rebate program, and a January 2026 voluntary agreement with the United States government.

To be clear about what is and is not established: no court or agency has found that AbbVie's practices violated any law; no enforcement action against AbbVie on these grounds has been announced; and this review located no reverse-discrimination lawsuit against the company. But practices like those documented above — an executive compensation goal category carrying a demographic strategy, demographically targeted sourcing, numeric race and sex targets for the lawyers staffed to company matters, and mentoring, sponsorship and internship programs described as being for diverse talent — are the categories these claims examine. For the complete framework — the four illegal DEI practice categories and when you can sue — see our guide, Is DEI Illegal? 4 Illegal DEI Practices & When You Can Sue.

Were you affected by these practices at AbbVie?

If you worked at AbbVie Inc. or one of its U.S. affiliates, or applied to the company, between roughly 2019 and 2025, the documented practices above may have touched your career in ways worth examining:

• You were passed over for a promotion during years when every executive carried an ESG goal category inside which senior leaders held "a goal aligned to executing the EEDI strategy," and cannot account for the decision against your record.
• You were never selected for the Executive Diversity Mentoring Program, the Executive Sponsorship Program, or a leadership program that the company described as being for "diverse talent" or "talent of diverse backgrounds" — programs whose entire function is to put an employee in front of the executives who decide promotions.
• You applied and never reached an interview during a period when AbbVie's published strategy named "attract and source talent" as a cornerstone with "implementation plans organized by business function and geography," and a dedicated recruiting team ran demographically targeted school partnerships.
• You are a lawyer at a firm doing AbbVie work whose staffing, hours or partnership prospects were affected by AbbVie's published targets — "at least 50% underrepresented lawyers serving on AbbVie matters," "[e]qual female and male partners serving on legal matters," minority partner representation moving "from 8% in 2018 to 15% by 2023" — measured, in AbbVie's words, by "the percentage of hours each group bills annually on AbbVie's matters."
• You were a manager, recruiter, HR or talent-acquisition professional who administered these goals — someone with first-hand knowledge of what the EEDI goals actually said, how they were scored, and what business functions were told to do about them.
• You were slotted into a process that was already decided. Sourcing and program-access rules injure the candidates they nominally favor too — being the diversity entry on someone's plan is not the same as being chosen.

There is a separate question worth asking if your work touched AbbVie's federal business. The False Claims Act's qui tam mechanism lets an individual bring a claim on the government's behalf, and potentially share in any recovery, where an organization certified compliance with federal anti-discrimination requirements while doing something else — the theory the Justice Department used against IBM and Deloitte. The Deloitte agreement adds a second route that is easy to miss: the government also contended that Deloitte "allocated costs to its federal government contracts relating to these practices and sought payment and reimbursement under its federal government contracts for such costs." Whether AbbVie made the certifications those theories depend on, what they said, and how program costs were treated are the sort of things an insider may know. Qui tam complaints are filed under seal, so a whistleblower's identity is initially protected while the government investigates. Both Title VII and the False Claims Act prohibit retaliation against people who assert their rights or report violations.

A federal settlement is not a substitute for your own claim: when the Justice Department resolved the Deloitte matter, it expressly preserved the EEOC's right to pursue charges alleging the very same conduct, and preserved individual liability. Nothing about that settlement compensated a single employee or applicant.

If any of these fits, it costs nothing to find out where you stand — meet our DEI discrimination lawyers, or start below.

What could a claim against AbbVie be worth?

Damages in individual discrimination cases

Back pay and front pay are uncapped under Title VII. Compensatory and punitive damages under Title VII are capped by employer size — $300,000 for employers with more than 500 employees, the bracket AbbVie occupies — but race claims under 42 U.S.C. § 1981 carry no damages cap at all, which is one reason race discrimination cases are often pleaded under it. Several state civil-rights statutes are likewise uncapped. Prevailing plaintiffs generally recover attorney's fees on top. For a sense of what employment discrimination cases can produce, Fett Law's own results include a $10.5 million race and age discrimination class action against Ford Motor Company, a $1.1 million jury judgment against the Michigan State Police, and a $460,000 reverse-discrimination settlement for three corrections officers. Prior results do not guarantee a similar outcome.

Whistleblower rewards under the False Claims Act

Under 31 U.S.C. § 3730(d), a qui tam relator receives 15–25% of the government's recovery when the Department of Justice intervenes, and 25–30% when the relator proceeds without intervention. The Deloitte settlement supplies a paid benchmark rather than a projection: the relator received $4,300,000 — exactly 20% of a $21,500,000 recovery. That settlement also shows why False Claims Act exposure outruns the money actually lost. Of the $21.5 million, $9,995,000 was restitution — roughly the government's single damages — so the resolution came to about 2.15 times the actual loss, because FCA recoveries are built on multiplied damages plus per-claim penalties. As a second illustration, arithmetic alone: an intervened case resolving at IBM's $17,077,043 would pay a relator roughly $2.6–$4.3 million. A contractor with a larger federal book or a longer conduct period could produce a materially larger number.

Class action potential

Class actions are built on a single policy applied to many people. A compensation goal category carried by every executive, or a program-nomination process run centrally, is by construction companywide. Historic employment-discrimination class settlements show the range such cases can reach: Coca-Cola paid $192.5 million (2000), Texaco $176.1 million (1996) and Novartis $175 million (2010) to resolve class claims.

Every case depends on its own facts — these figures show the range the law makes possible, not a promise of any outcome. The fastest way to learn where your situation falls is to start a confidential intake or request a free consultation.

Sources